Operating

D&A

Bristol-Myers Squibb D&A decreased by 3.4% to $977.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 48.0%, from $1.88B to $977.00M. Over 4 years (FY 2021 to FY 2025), D&A shows a downward trend with a -21.7% CAGR.

Analysis

StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025

How to read this metric

Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.

Detailed definition

This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...

Peer comparison

Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.

Metric ID: cf_depreciation_and_amortization

Historical Data

19 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Value$2.71B$2.73B$2.58B$2.58B$2.58B$2.59B$2.52B$2.43B$2.43B$2.44B$2.46B$2.53B$2.60B$2.59B$1.88B$1.01B$1.01B$1.01B$977.00M
QoQ Change+0.6%-5.4%+0.2%-0.0%+0.2%-2.6%-3.6%+0.1%+0.1%+1.2%+2.8%+2.5%-0.2%-27.5%-46.2%-0.1%+0.0%-3.4%
YoY Change-4.8%-5.1%-2.2%-6.0%-5.8%-5.9%-2.3%+4.2%+6.7%+6.4%-23.7%-60.0%-61.1%-61.0%-48.0%
Range$977.00M$2.73B
CAGR-20.3%
Avg YoY Growth-17.9%
Median YoY Growth-5.8%

Frequently Asked Questions

What is Bristol-Myers Squibb's d&a?
Bristol-Myers Squibb (BMY) reported d&a of $977.00M in Q4 2025.
How has Bristol-Myers Squibb's d&a changed year-over-year?
Bristol-Myers Squibb's d&a decreased by 48.0% year-over-year, from $1.88B to $977.00M.
What is the long-term trend for Bristol-Myers Squibb's d&a?
Over 4 years (2021 to 2025), Bristol-Myers Squibb's d&a has grown at a -21.7% compound annual growth rate (CAGR), from $10.69B to $4.01B.
What does d&a mean?
The accounting process of spreading the cost of physical and intangible assets over time.